← Back to patent-cliff list
Paclitaxel/Encequidar mesylate
Tier C — Watch / tradePaclitaxel/Encequidar mesylate
韩美药品株式会社
Originator
2019
First approval
-
Expiry (public)
No sales data
Peak sales
化学药
Type
Targets：PGY1、Tubulin
Brand：Oraxol、Ohraksol
Indications (approved)：乳腺癌、腺癌
Regional status
US
临床二期
2018-12-21
EU
临床二期
2015-09-23
China
临床一期
2019-04-22
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Paclitaxel/Encequidar mesylate?
Approved indications include: 乳腺癌, 腺癌.
When does the Paclitaxel/Encequidar mesylate patent expire?
No public expiry year is available for Paclitaxel/Encequidar mesylate yet; this page updates once verified.
How do I get a quote for Paclitaxel/Encequidar mesylate intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-24